Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis.
Lorenzo PortaSih-Shiang HuangChen WeiChin-Hua SuWan-Ting HsuWang-Huei ShengChien-Chang LeePublished in: PloS one (2022)
Physicians should avoid routine methylprednisolone use in SARS-CoV-2 patients, since it does not reduce 30-day mortality. However, they must consider its use for severe patients with cardiovascular or respiratory comorbidities in order to reduce the incidence of either shock or acute respiratory failure.
Keyphrases
- sars cov
- respiratory failure
- end stage renal disease
- coronavirus disease
- high dose
- extracorporeal membrane oxygenation
- ejection fraction
- primary care
- risk factors
- chronic kidney disease
- liver failure
- prognostic factors
- mechanical ventilation
- respiratory syndrome coronavirus
- low dose
- coronary artery disease
- drug induced
- combination therapy
- intensive care unit
- cardiovascular events
- early onset
- acute respiratory distress syndrome
- patient reported
- aortic dissection